Salvatore Corallo

The Pan-Immune-Inflammation Value is a new prognostic biomarker in metastatic colorectal cancer: results from a pooled-analysis of the Valentino and TRIBE first-line trials

Giovanni Fucà, Vincenzo Guarini, Carlotta Antoniotti et al. · British Journal of Cancer · 2020 · 315 citations · Full text

Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial

Chiara Cremolini, Carlotta Antoniotti, Daniele Rossini et al. · The Lancet Oncology · 2020 · 309 citations · Full text

Oncology, Medicine, Colorectal Cancer +8

Biomarkers of Primary Resistance to Trastuzumab in HER2-Positive Metastatic Gastric Cancer Patients: the AMNESIA Case-Control Study

Filippo Pietrantonio, Giovanni Fucà, Federica Morano et al. · Clinical Cancer Research · 2017 · 107 citations · Full text

Class 1, 2, and 3 <i>BRAF</i> -Mutated Metastatic Colorectal Cancer: A Detailed Clinical, Pathologic, and Molecular Characterization

Marta Schirripa, Paola Biason, Sara Lonardi et al. · Clinical Cancer Research · 2019 · 104 citations · Full text

Maintenance Therapy With Panitumumab Alone vs Panitumumab Plus Fluorouracil-Leucovorin in Patients With <i>RAS</i> Wild-Type Metastatic Colorectal Cancer

Filippo Pietrantonio, Federica Morano, Salvatore Corallo et al. · JAMA Oncology · 2019 · 103 citations · Full text